KaydedilenlerDerginizi ekleyin

Dergiler / European Journal of Rheumatology / 2014 / Cilt: 1 - Sayı: 4

Severe candida laryngitis in a patient with rheumatoid arthritis treated with adalimumab

Oğuz GÜÇLÜ
Hatice YILMAZ
Zerrin ÖĞRETMEN
Şenol KOBAK
Sayfa
167–169
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Adalimumab was discontinued, and the infection was controlled with anti-fungal treatment

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Rheumatoid arthritis is a chronic erosive rheumatic disease that can present with polyarticular involvement.
📊
Temel Bulgular & Veri:In this report, we report a 52-year-old male patient using adalimumab for active rheumatoid arthritis who presented to our polyclinic with generalized mouth and throat sores, hoarseness, and swallowing difficulty.
💡
Sonuç & Katkı:Adalimumab was discontinued, and the infection was controlled with anti-fungal treatment
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Rheumatoid arthritis is a chronic erosive rheumatic disease that can present with polyarticular involvement. Anti-TNF-alpha drugs are used in cases that are resistant to traditional disease-modifying antirheumatic drugs (DMARDs). Anti-TNF-alpha drugs are groundbreaking drugs, the efficacy of which has been proven in the treatment of rheumatoid arthritis. However, the data concerning safety remain limited and contradictory. The risk of tuberculosis reactivation, various infections, as well as lymphoproliferative disease and/or secondary malignancy is a matter of discussion. In this report, we report a 52-year-old male patient using adalimumab for active rheumatoid arthritis who presented to our polyclinic with generalized mouth and throat sores, hoarseness, and swallowing difficulty. Candida laryngitis was detected in the laryngoscopy and culture samples. Adalimumab was discontinued, and the infection was controlled with anti-fungal treatment

🔖

Bu Makaleye Atıf Yap

GÜÇLÜ, O., YILMAZ, H., ÖĞRETMEN, Z., KOBAK, Ş. (2022). Severe candida laryngitis in a patient with rheumatoid arthritis treated with adalimumab. European Journal of Rheumatology, Cilt: 1 - Sayı: 4, 167–169. https://ajindex.com/articles/511877

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necro- sis factor agents and tuberculosis risk: mecha- nisms of action and clinical management. Lan- cet Infect Dis 2003
  2. [CrossRef] Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD
  3. Biobadaser Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter ac- tive-surveillance report. Arthritis Rheum 2003, 48: 2122-7. [CrossRef] 168 Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, et al. Updated consen- sus statement on biological agents for the treat- ment of rheumatic diseases, 2008. Ann Rheum Dis 2008
  4. . 67 Suppl 3: p. iii2-25. [CrossRef] Jassal, MS, Bishai WR. The risk of infections with tumor necrosis factor-alpha inhibitors. J Clin Rheumatol 2009
  5. [CrossRef] Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional com- parisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002
  6. [CrossRef] Lügering A1, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a cas- pase-dependent pathway. Gastroenterology 2001
  7. [CrossRef] Warris, A, Bjorneklett A, Gaustad P. Invasive pulmo- nary aspergillosis associated with infliximab ther- apy. N Engl J Med, 2001
  8. [CrossRef] Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threat- ening histoplasmosis complicating immuno- therapy with tumor necrosis factor alpha an- tagonists infliximab and etanercept. Arthritis Rheum 2002
  9. [CrossRef] van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, van der Spoel JI, Wester JP, Zand- stra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infec- tion in a patient with infliximab and methotrexate. Intensive Care Med 2003
  10. [CrossRef] Tsiodras S, Samonis G, Boumpas DT, Kontoyian- nis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008
  11. [CrossRef] Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized control